Effectiveness of KeraStat Gel for Improved Cosmesis of Partial Thickness Burns



Status:Recruiting
Conditions:Hospital
Therapuetic Areas:Other
Healthy:No
Age Range:6 - 100
Updated:8/10/2018
Start Date:August 31, 2018
End Date:October 31, 2019
Contact:Alexis Rejeski Gabard, MS
Email:alexis.gabard@keranetics.com
Phone:336-575-2278

Use our guide to learn which trials are right for you!

A randomized, controlled, 30-subject, within-subject trial for examining the effectiveness of
KeraStat Gel, as opposed to the institutional standard of care, silver sulfadiazine, in
improving cosmesis of the healed wound.

The study seeks to determine whether the use of KeraStat Gel as the primary dressing for
partial thickness burns results in improved cosmesis of the healed wound, and results in less
painful dressing changes, faster reepithelialization, and reduction in need for excision and
grafting. The study will enroll 30 subjects. The study design is a randomized, controlled,
within-subject trial to compare the effectiveness of KeraStat Gel vs. standard of care (SOC),
silver sulfadiazine (SSD). Each of two distinct burns will be randomized to the use of
KeraStat Gel or SOC. Patients will be seen weekly for the first month and then at months 3,
6, and 12 post burn.

Inclusion Criteria:

- Presenting with at least two comparable, discrete, and separate partial thickness
thermal burns, as determined by the Investigator, measuring 50 - 1,000 cm2 each

- Study wounds identified are partial thickness depth

- KeraStat Gel and SSD can be applied to randomized study burn wounds as definitive care
treatment within 24 hours from time of injury]

- Overall total body surface area burned < 20%

Exclusion Criteria:

- Pregnant or nursing

- Prisoner

- Presence of inhalation injury, as determined by the Investigator

- Injury requiring formal intravenous fluid resuscitation

- Concomitant non-thermal traumatic injuries

- Chronic medical conditions including, but not limited to, documented renal impairment
(Cr > 2.5 mg/dL), hepatic impairment (Total bilirubin > 2.5 mg/dL), thromboembolic
disorders, active infection in study wound areas, uncontrolled diabetes (HbA1C > 7%),
HIV infection, history of melanoma or systemic malignancy within the last 10 years

- Receiving corticosteroids, immunosuppressive agents, radiation or chemotherapy,
topical growth factors, or any other medication the Investigator feels will affect
wound healing

- Not expected to live at least 13 months post-burn

- Received an investigational drug or biologic within 3 months prior to injury

- Previously treated with a skin graft at either of the treatment sites

- Chemical or electrical burn

- Known or documented allergy to sulfonamides

- Proposed study wounds are full thickness

- Any condition the Investigator determines will compromise subject safety or prevent
the subject from completing the study
We found this trial at
1
site
1 Medical Center Blvd
Winston-Salem, North Carolina 27157
336-716-2011
Phone: 336-716-8040
Wake Forest University Health Sciences Welcome to Wake Forest Baptist Medical Center, a fully integrated...
?
mi
from
Winston-Salem, NC
Click here to add this to my saved trials